Periodontal Therapeutics Market

SKU: DMPH1888 | Last Updated On: Sep 20 2022 | Available Formats

>Periodontal Therapeutics Market Expected to reach at a high CAGR of 8.60% by 2029:

Periodontal Therapeutics Market is segmented By Therapeutic Type (Systemic Antibiotics (Doxycycline, Minocycline, Metronidazole, and Others), Local Antibiotics (Arestin, Atridox, PerioChip, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-commerce), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Periodontal Therapeutics Market size was valued at USD 686.3 million in 2021 and is estimated to reach at a compound annual growth rate (CAGR) of 8.60% over the forecast period 2022 to 2029.

Periodontal disease, commonly known as gum disease, is where the periodontal tissues surrounding the teeth are in a pathological inflammatory condition. Periodontitis is relatively common, usually caused by poor oral hygiene, and can be prevented in most cases. Periodontitis can lead to tooth loss and is a risk factor for heart and lung diseases. Its symptoms include red, swollen and tender gums. Periodontal therapeutics is a non-surgical treatment for periodontal diseases.

Periodontal Therapeutics Market Dynamics

Periodontal therapeutics market growth is driven by the rising prevalence of periodontal disease, robust pipeline drugs, and a surge in awareness about oral health.

A robust pipeline of drugs is expected to drive market growth.

The periodontal therapeutics market is witnessing many clinical developments and product launches, resulting in increased prescription and market demand. Large pharmaceutical companies and healthcare associations are focusing on advanced therapeutics for the non-surgical treatment of gum disease. The use of antibiotics, particularly systemic antibiotics, as first-line therapy in periodontitis is rapidly growing with the innovation of new products. These innovations are likely to cater to the unmet needs of periodontal disease patients globally.

Biological therapeutics is another key area of development in the periodontal therapeutics market. With increasing evidence of the role of biologics in dental health, the focus is on promoting biologic agents for periodontal regeneration. For instance, in July 2021, Cortexyme, Inc. initiated new preclinical data demonstrating efficacious dose range finding data for its lead drug candidate atuzaginstat (COR388) in periodontal disease, as well as its participation in the 2021 General Session & Exhibition of the International Association for Dental Research (IADR), a virtual event.

Using alternative oral hygiene products is expected to hamper the market growth.

While surgical interventions and non-surgical treatment have been the most widely used procedures of periodontal treatment globally, adjuvant therapies are still in the nascent application stage. Also, the oral health industry is rapidly transforming, with oral hygiene products protruding into the oral health spectrum. The development of toothpaste and gels is likely to lower the use of therapeutics. Furthermore, these non-prescription products are likely to improve the overall oral health of users, thereby reducing the risk of periodontal diseases over the long run. Specially formulated toothpaste with functional claims towards healing bleeding gums, improving the seal between teeth and gums, and helping with gingivitis are hitting the market. Mouth cleansers to help freshen breath and reduce mouth bacteria are another key product category attracting development towards oral health.

For instance, a germicidal mouthwash based on Chlorhexidine gluconate is widely prescribed by dentists to prevent or lower the risk of periodontal disease and as a post-treatment adjuvant.

Industry Analysis

The periodontal therapeutics market provides in-depth analysis of the market based on various industry factors such as epidemiology, unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

COVID-19 Impact Analysis

The outbreak of COVID-19 has hurt the global periodontal therapeutics market. The sales growth of antibiotics for periodontal disease treatment slightly declined in 2020, owing to reduced hospital visits for dental services and prescriptions from dentists globally. Healthcare facilities worldwide faced unprecedented situations due to the rapid spread of novel coronavirus with overburdening diagnostics, in-patient care, and post-recovery complexities. Most dental care services are considered ‘non-essential’ by the population, dental providers, and healthcare bodies in response to the pandemic. In the Centers for Medicare & Medicaid Services (CMS) in March 2020 recommended dental providers in clinics and hospitals across the U.S. limit non-essential dental, medical, and surgical procedures to reduce the spread of viruses and conserve medical PPEs. This has resulted in a significant drop in several periodontal treatments, including surgical and non-surgical. However, adjuvant therapies, including antibiotics, are relatively resilient over surgical treatment procedures owing to over-the-counter sales.

Periodontal Therapeutics Market Segment Analysis

The chlorhexidine segment is expected to hold the largest market share in the periodontal therapeutics market.

The main ingredient in most mouthwashes geared toward patients suffering from gum disease is chlorhexidine. Using chlorhexidine mouthwashes is an excellent way to maintain and treat mild forms of gum disease. Bleeding gums treatment almost always includes the use of chlorhexidine mouthwash. Chlorhexidine gluconate is a prescription antiseptic used in dentistry to fight bacteria in the oral cavity that contribute to gum disease. The most common form of this antiseptic is oral rinses, but it can also be available in gels or small chips inserted into the gingival sulcus. Chlorhexidine (marketed as the prescription-only brands Peridex, PerioChip, PerioGard, Denti-Rinse, Paroex, and Acclean) is an antimicrobial used to control plaque and gingivitis in the mouth or periodontal pockets. For instance, Medicom, Denti-Care Denti-Rinse Chlorhexidine Oral Rinse Gluconate mint provides an extra boost to reduce tissue inflammation and bleeding and is ideal for periodontitis and oral irrigation. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period. ​ ​

Periodontal therapeutics Market Scope

Metrics

Details

Market CAGR

8.60%

Segments Covered

By Type, By Treatment, By Distribution Channel, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

Periodontal Therapeutics Market Geographical Analysis

North American region is expected to hold the largest market share in the global periodontal therapeutics market.

North America accounts for the most significant market share in the global market. It is mainly attributed to the growing patient pool with periodontal diseases, increasing geriatric population, and diabetic population in the region. Moreover, other factors increasing the regional market share are the rise in healthcare expenditure, advanced healthcare infrastructure, high level of drug development, established market players, high investment in R&D activities by key players, and a proper regulatory framework for periodontal drugs. For instance, in August 2021, NIH awarded a $2M grant to ADA Science & Research Institute, the University of Pennsylvania, to study oral mucosa. The American Dental Association Science & Research Institute, together with the University Of Pennsylvania School Of Dental Medicine, will evaluate the mechanisms that maintain and damage the barrier function of oral epithelium in periodontal disease and peri-implantitis.

 The United States is leading the North American periodontal therapeutics market. According to the CDC, periodontitis, a more severe periodontal disease, affects 50 percent of Americans aged 30 and up. It is around 64.7 million people in the United States. In addition, 64 percent of persons 65 and older in the study had moderate or severe periodontitis. This figure is significantly higher than prior national figures. The number of Americans aged 65 and older will double over the next 40 years, reaching 80 million in 2040. The number of adults ages 85 and older will nearly quadruple between 2000 and 2040. Hence, with the growing aging population and an increasing number of patients with periodontal diseases, the market for periodontal therapeutics is expected to grow.

Periodontal Therapeutics Market Competitive Landscape

Major key players in the periodontal therapeutics market are Kraken Pharmaceutical Co. Ltd, OraPharma Inc, Colgate-Palmolive, Xttrium Laboratories, Inc., Medicom, Pfizer Inc, 3M, Den-Mat Holdings LLC, Dexcel Pharma, Bausch Health (Valeant).

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

­Product Portfolio:

Flagyl Oral Formulation (metronidazole oral formulation): Metronidazole is an agent with reported success in the treatment of anaerobic periodontal infections.

The global periodontal therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

 

Frequently Asked Questions

What is the Projected CAGR value of the Periodontal Therapeutics Market?

Periodontal Therapeutics Market is expected to grow at a CAGR of 8.6% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Periodontal Therapeutics Market during 2022-2029

Which is the fastest growing region in the Periodontal Therapeutics Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period 

Trending Topics

Scleroderma Therapeutics Market

Xerostomia Therapeutics Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest